CompletedPhase 1NCT03379311
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Studying Atopic keratoconjunctivitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allakos Inc.
- Principal Investigator
- Quan D Nguyen, MD, MScStanford University
- Intervention
- AK002(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2018 – 2019
Study locations (8)
- Byers Eye Institute at Stanford University, Palo Alto, California, United States
- Riverside Clinical Research, Edgewater, Florida, United States
- University of Maryland, Department of Ophthalmology and Visual Sciences, Baltimore, Maryland, United States
- Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, United States
- Tauber Eye Center, Kansas City, Missouri, United States
- Ophthalmology Associates, St Louis, Missouri, United States
- Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States
- UPMC Eye Center, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03379311 on ClinicalTrials.govOther trials for Atopic keratoconjunctivitis
Additional recruiting or active studies for the same condition.